Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation

López-Beltrán, Antonio; Liu, Cheng; Andersson, Lennart; Brausi, Maurizio; Matteis, A. De; Montironi, Rodolfo; Sesterhenn, Isabell A.; Kwast, Theodorus H. van der; Mazerolles, Catherine

doi:10.1007/s00428-001-0577-6

Cited by 103 publications

(102 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these 70 cases, there were 24 (34%), which contained microinvasion. Of the patients with microinvasion, 5.8% had lymph node metas- 51 Further investigation is warranted to define the clinical significance of this diagnostic category.…”

Section: Microinvasive Carcinomamentioning

confidence: 99%

Staging and reporting of urothelial carcinoma of the urinary bladder

et al. 2009

Self Cite

View full text Add to dashboard Cite

Section: Microinvasive Carcinomamentioning

confidence: 99%

Staging and reporting of urothelial carcinoma of the urinary bladder

et al. 2009

Self Cite

View full text Add to dashboard Cite

“…Our finding of epimutations in normal appearing mucosa and concordant tumor samples supports the idea that the entire epithelium may be predisposed to premalignant change. 55 Tumor contamination of normal samples is possible but unlikely since these samples were carefully microdissected. Although not statistically significant, our findings do suggest a role for field cancerization through epigenetic changes.…”

Section: Discussionmentioning

confidence: 99%

Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder

et al. 2008

Self Cite

View full text Add to dashboard Cite

Small-cell carcinoma of the urinary bladder (SCBC) is a rare tumor, which shows a common clonal origin with urothelial carcinoma. It bears a high metastatic potential, even when discovered in a localized state. Identifying the molecular underpinnings of this disease may elucidate useful clinical information regarding prevention, diagnosis, prognosis, treatment, and surveillance. As DNA methylation is widely recognized as having a pivotal role in the process of carcinogenesis, we analyzed the DNA methylation status of four frequently hypermethylated tumor suppressors in small-cell and transitional-cell carcinoma (TCC) arising concomitantly in 13 patients. Fourteen cases of pure TCC were also included in the analysis. We identified frequent methylation of RASSF1 and MGMT and infrequent methylation of MLH1 and DAPK1 in cases of concomitant TCC and SCBC. Similar rates of methylation were found in pure and concomitant histopathologies, with the exception of MGMT, which was much less frequently methylated in pure TCC. These findings suggest that SCBC and TCC have common origins, establish DNA methylation of some tumor suppressors as frequent occurrences in both histopathologies, and suggest that MGMT methylation may be an SCBC-specific epimutation. Modern Pathology (2008) 21, 355-362; doi:10.1038/modpathol.3801012; published online 11 January 2008Keywords: urinary bladder; small-cell carcinoma; DNA methylation; epigenetics DNA methylation-induced silencing of gene expression is now recognized as an important contributor in all stages of carcinogenesis. 1 Methylation of CpGdense regions, or CpG islands (CpGIs), associated with the first exons of many genes, serves to recruit transcriptional silencing machinery, including methyl-CpG-binding proteins, histone deacetylases and methyltransferases, and ATP-dependent chromatin-remodeling enzymes. 2,3 Silencing of key tumor and metastasis suppressors, 4,5 drug-metabolizing enzymes, 6 and DNA-repair proteins 7 is an event that contributes to carcinogenesis, acquisition of invasiveness and metastatic potential, angiogenesis, and therapy refractoriness. DNA methylation is a target for both therapeutic and biomarker purposes. 8 Importantly, the study of DNA methylation in clinical samples may provide useful and novel insights into the pathobiology of disease processes such as cancer.Transitional-cell carcinoma (TCC) arises from urothelium, which lines the bladder, as well as the renal pelvis, ureter, and portions of the urethra. Although infrequent in occurrence, small-cell bladder cancer (SCBC) may evolve or co-evolve from pre-existing TCC. 9 We hypothesized that DNA methylation of specific genes may underlie the pathogenesis of SCBC. In this study, we quantitatively analyzed the methylation status of RASSF1,

show abstract

“…Several studies have demonstrated increasing incidence if associated with Cis or papillary carcinoma, but we lack recent studies concerning prognosis of isolated lesions (1,24). One reason for the lack of data might be the problem of reproducibility in grading dysplasia (12,13,25,26).…”

Section: Low Grade Urothelial Dysplasia (Lgud)mentioning

confidence: 98%

“…FUH was mostly seen in cases of follow-up of pTa tumors and generally considered as a minor finding. Several studies could demonstrate genetic abnormalities already present in hyperplasia such as loss of heterozygosity of FGFR-3 gene and deletion of chromosome 9 in 70% of FUH (10)(11)(12). This raises the question of whether FUH should be considered as detection of an early premalignant urothelium lesion with low-risk profile (13).…”

Section: Flat Urothelial Hyperplasia (Fuh)mentioning

confidence: 99%

See 1 more Smart Citation

Fluorescence diagnosis and flat lesions of urothelium: New challenges for pathologists and urologists (Review)

Compérat¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Bladder cancer is a common malignancy. Recurrence rate and progression vary greatly depending on factors such as tumor multiplicity, size, previous recurrence rates, tumor stage, tumor grade and the presence of carcinoma in situ. Treatment is expensive, recent studies demonstrated that superficial bladder cancer is a major economic burden. It is necessary to establish new kinds of techniques to improve diagnosis, therapy and follow-up, such as fluorescence diagnosis, without adding significant risk of complications. As urologists have a better sight of bladder lesions with fluorescence diagnosis, pathologists will be asked in the future to evaluate more frequently flat lesions, which up to now would not have been a matter of concern. For several reasons it is very important to have accurate and precise definitions of these flat lesions. First to permit uniform treatment of large groups of patients and second to see in large cohorts the evolution and natural history of several flat lesions, not always well known up to now. The aim of the study was to review the most important flat lesions, to demonstrate the difficulty of classifying several lesions, to introduce to urologists the new problems linked to FD and to suggest new models for accurate analysis. How far can we go in our answer as pathologists and how will it change the patient management?

show abstract

Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation

Cited by 103 publications

References 55 publications

Staging and reporting of urothelial carcinoma of the urinary bladder

Staging and reporting of urothelial carcinoma of the urinary bladder

Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder

Fluorescence diagnosis and flat lesions of urothelium: New challenges for pathologists and urologists (Review)

Contact Info

Product

Resources

About